Welcome to Markets Desk, here's what's moving the needle this afternoon.
With midterm elections now just one month out, history offers a clear signal for equity investors. Going back nearly a century, markets have tended to perform well in the twelve months following midterm votes, regardless of which party gains ground, suggesting the uncertainty itself may be the bigger headwind than the outcome.
Shifting to labor, the September jobs report has traders recalibrating their read on the economy. Hiring came in soft, and the broader picture suggests workers are finding it harder to land new positions. The Federal Reserve will be watching closely, as a cooling labor market could influence the pace and timing of any future policy moves.
And in pharmaceuticals, Novo Nordisk is planning a United States launch of denecimab in the first half of two thousand twenty seven, even as the FDA has extended its review timeline for the haemophilia A treatment. The delay introduces some uncertainty around near-term revenue expectations for the Danish drugmaker, though management appears confident the regulatory path forward remains intact.
That's the tape. Markets Desk, signing off the floor.
